BCRX
BioCryst Pharmaceuticals Inc
8.80$
+0.9%
vs. previous close
Closing price · As of: Sep 21, 2026
Statements
Cash Flow
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +1.7% | +168.3% | +45.8% | +9.4% | -6.0% | +3.3% | +3.9% | +84.9% | +15.2% | -24.7% | +11.5% | |
| – | -4.6% | -12.6% | +48.7% | -25.6% | +88.6% | -16.5% | +134.1% | +29.0% | +24.4% | +17.6% | +30.0% | |
| – | +111.0% | -25.1% | +76.5% | -23.0% | +72.8% | -14.6% | +114.0% | +329.8% | – | – | – | |
| – | +1,357.1% | -139.7% | – | -137.8% | – | – | -69.8% | -825.6% | – | – | – | |
| – | +4,732.1% | +3.0% | -93.8% | +11.6% | -6.3% | +49.9% | +364.0% | -43.4% | +60.5% | -48.2% | +119.6% | |
| – | -55.0% | – | -384.4% | – | +1,534.5% | -108.8% | – | -911.4% | +2.5% | – | -126.0% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | -95.1% | -94.2% | +42,670.0% | -58.5% | +41.5% | +38.8% | -40.5% | – | – | – | – | |
| – | +0.0% | -1.4% | -99.5% | +5,086.9% | +207.8% | +246.3% | +335.7% | -75.1% | -20.1% | -102.9% | +17,622.4% | |
| – | -95.1% | +325.3% | +482.3% | -53.9% | +58.5% | +205.5% | +18.8% | -75.5% | -63.1% | -117.7% | +5,670.6% | |
| – | -176.8% | – | – | -189.8% | – | +81.4% | +47.1% | -186.3% | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – |
Data as of: September 21, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.